News | Annuloplasty Rings | September 10, 2015

Carillon Mitral Contour System Deemed Cost-Effective Treatment for Functional Mitral Regurgitation

German study finds mitral annuloplasty treatment offers more benefit at lower cost compared to optimal medical treatment

Carillon mitral contour system, cost-effective, optimal medical treatment, OMT, TITAN, functional mitral regurgitation, FMR

Carillon mitral contour system image courtesy of Cardiac Dimensions Inc.

September 10, 2015 — The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical regimen of optimal medical treatment (OMT), the present standard of care for functional mitral regurgitation (FMR). This finding has been established in a new study published in BMC Cardiovascular Disorders.

Researchers analyzed data derived from the landmark TITAN clinical trial, which demonstrated significant clinical merits of the Carillon technology, and developed a comprehensive cost-effectiveness model that projects the costs of the technology and compares them to the benefits. The output shows the Carillon therapy to be cost-effective in comparison to OMT with an incremental cost-effectiveness ratio (ICER) of €15,533 per quality-adjusted life year (QALY).

ICER is considered to be a gold standard in terms of determining whether a new therapy is cost-effective, with amounts below €35,000/QALY typically considered to be cost effective. The analysis was conducted from the perspective of the German health insurance system.

“In multiple clinical trials, Carillon has demonstrated significant reductions in FMR and improvement in heart failure symptoms. This analysis takes the next step in projecting that these benefits result in the cost effectiveness of the therapy,” said Michael Haude, M.D. Ph.D., chief of cardiology at Lukaskrankenhaus in Neuss, Germany, and co-author of the study. “This positive assessment has substantial implications in terms of the utility and accessibility of the therapy.”

The Carillon mitral contour system is a percutaneous mitral annuloplasty treatment option that can be deployed rapidly and safely, utilizing standard interventional techniques. The implantable device consists of a distal anchor and a proximal anchor connected by a shaping ribbon and utilizes the heart’s venous anatomy to reshape the mitral annulus. This approach allows for reduction of the dilated annulus, addressing a root cause of FMR. The system has demonstrated compelling efficacy, significantly improving patients’ symptoms, mitral regurgitation and quality of life. In addition, all adjunctive treatment options remain available after using Carillon, making it an ideal first-line therapy for FMR.

For more information: www.cardiacdimensions.com

Related Content

 Medtronic Evolut TAVR Cleared in Canada for Both Bicuspid Valves in Intermediate or Greater Risk and for All Low Risk Patients for TAVR
News | Structural Heart | January 11, 2021
January 11, 2021 — Medtronic has received a new expanded indication from Health Canada for its Evolut Transcatheter A
The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to P+F Products + Features GmbH TricValve Transcatheter Bicval Valves System. The system uses two self-expanding valves in the vena cava for the treatment of patients with hemodynamically relevant tricuspid insufficiency without the need to touch the native tricuspid valve. #TTVR

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to P+F Products + Features GmbH TricValve Transcatheter Bicval Valves System. The system uses two self-expanding valves in the vena cava for the treatment of patients with hemodynamically relevant tricuspid insufficiency without the need to touch the native tricuspid valve.

News | Structural Heart | January 06, 2021
January 6, 2021 — The U.S.
First Patient Treated With Harpoon Transcatheter Mitral Valve Repair Device in U.S. Trial. #TMVR
News | Structural Heart | December 29, 2020
December 29, 2020 — Edwards Lifesciences announced Dec.
Health Canada has approved the expanded use of the Edwards Lifesciences Sapien 3 and Sapien 3 Ultra transcatheter aortic valve replacement (TAVR) heart valves for the transfemoral treatment of patients diagnosed with severe symptomatic aortic stenosis who are at low risk for open-heart surgery. #TAVR #TAVI
News | Structural Heart | December 29, 2020
December 29, 2020 — Health Canada has approved the expanded use of the Edwards Lifesciences Sapien 3 and Sapien 3 Ult
An example of a 80-year-old TAVR patient planning CT scan from Northwestern Medicine's Central DuPage Hospital. This was used in a heart team meeting with the TAVR staff, including a cardiac surgeon and interventional cardiologist, to determine if this patient was eligable for TAVR, the best access routes to deliver the valve, device valve size needed, and to look for any potential anatomical issues so they can be planned for. 

An example of a 80-year-old TAVR patient planning CT scan from Northwestern Medicine's Central DuPage Hospital. This was used in a heart team meeting with the TAVR staff, including a cardiac surgeon and interventional cardiologist, to determine if this patient was eligible for TAVR, the best access routes to deliver the valve, device valve size needed, and to look for any potential anatomical issues so they can be planned for.

News | Structural Heart | September 02, 2020
September 2, 2020 — Northwestern Medicine Bluhm Cardiovascular Institute physicians recently completed their 2,000th
Neovasc Files CE Mark for Tiara TA Transapical Mitral Valve Replacement System. TMVR
News | Structural Heart | May 29, 2020
May 29, 2020 — Neovasc Inc., developer of a minimally invasive transcatheter mitral valve replacement (TMVR) technolo
Videos | Structural Heart | April 01, 2020
A review of the PARTNER 3 Low-Risk Trial with ...